Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia

European Urology
Frans DebruyneDmitrii L Arustamov

Abstract

Pilot studies with daily dosing suggested the use of the luteinizing hormone-releasing hormone antagonist cetrorelix (CET) for the treatment of symptoms from benign prostatic hyperplasia (BPH). To assess efficacy and safety of three dosing schemes of CET in patients with symptomatic BPH. After a run-in period with 4 weekly injections of placebo, 140 patients with an international prostate symptoms score (IPSS) > or =13 and a peak urinary flow rate (PFR) 5-13ml/s were randomly allocated to 4 treatment groups; patients with residual urine volume of >350ml were excluded. Patients received either CET at dosages of 5mg/wkx4, 10mg/2 wkx2 or 10mg/wkx4 or placebo. IPSS, PFR and mean uroflow, residual urinary volume, prostate volume, plasma testosterone, quality of life, and sexual function were evaluated over a total of 20 wk after randomization. Of 140 randomized patients, one patient did not complete treatment, 5 others dropped out off-treatment, before week 12 evaluation of the primary end point. In all CET groups a rapid improvement in mean IPSS was obtained, with a peak effect of -5.4 to -5.9 (placebo: -2.8). After all dosages of CET given, changes from baseline and differences to placebo were statistically significant up to week ...Continue Reading

References

Aug 22, 1996·The New England Journal of Medicine·P C Walsh
Jan 1, 1997·Annual Review of Medicine·M Barry, C Roehrborn
Dec 26, 2001·Urology·S J JacobsenM M Lieber
Dec 19, 2003·The New England Journal of Medicine·John D McConnellUNKNOWN Medical Therapy of Prostatic Symptoms (MTOPS) Research Group
May 2, 2006·European Urology·Andrea Tubaro
Jul 19, 2006·European Urology·Annie HutchisonRemigio Vela Navarrete
Jul 25, 2006·European Urology·Frans M J Debruyne
Apr 10, 2007·European Urology·Stephan MadersbacherGeorg Schatzl

❮ Previous
Next ❯

Citations

Jun 12, 2012·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Dong YangBing Li
Apr 9, 2011·Current Urology Reports·Brian A Parsons, Hashim Hashim
Nov 26, 2015·Clinical Investigation·Kouji IzumiChawnshang Chang
Mar 2, 2010·Women's Health·Monika VijLinda Cardozo
Nov 27, 2009·Expert Opinion on Therapeutic Patents·Gábor Mezo, Marilena Manea
May 20, 2015·Expert Opinion on Investigational Drugs·Kanika GuptaJeanny B Aragon-Ching
Apr 14, 2010·Expert Opinion on Emerging Drugs·Monika VijLinda Cardozo
Jan 16, 2013·Expert Opinion on Investigational Drugs·Stavros Gravas, Jean J M C H de la Rosette
May 8, 2010·Expert Opinion on Emerging Drugs·Hashim Hashim, Paul Abrams
Mar 18, 2011·British Journal of Pharmacology·S VenturaB Exintaris
Jan 8, 2010·BJU International·Roger S KirbyNoel Clarke
Dec 14, 2011·Scandinavian Journal of Urology and Nephrology·Louise L KlarskovNiels Svolgaard
Jan 1, 2010·Hormone Molecular Biology and Clinical Investigation·Karoly SzepeshaziAndrew V Schally
Dec 4, 2012·Current Opinion in Urology·Ferenc G RickAndrew V Schally
May 19, 2009·Current Opinion in Urology·Karl-Erik AnderssonAlan J Wein
Aug 23, 2017·Expert Opinion on Emerging Drugs·Dominique ThomasAlexis Te

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.